RSV-A (A2 Strain) Purified Virus

Catalog #: 10-247-000

Size: 1.0 mg

In Stock

Biological Substance B

This material requires a signed and fully executed Advanced Biotechnologies Inc agreement with possible fees, prior to purchase. To begin this process, please complete the Intended Use form and return it to agreements@abionline.com.

Intended Use Form

DETAILS RESOURCES RELATED PRODUCTS

Human Respiratory Syncytial Virus subtype A (A2 Strain) propagated in HEp-2 cells and purified from culture supernatant and cells showing cytopathic effect.

≥ 5 x 10⁹ viral particles per mL of purified RSV-A

≥ 10^6.0 TCID₅₀ per mL of purified RSV-A

For research use only.

APPLICATION FOR USE

In vitro Infectivity Assay
Antiviral Studies
Animal Experimentation
Nucleic Acid Extraction
Spiking Studies
ELISpot Assay
Virus Neutralization Assay
Virus Ultrastructural Studies

QUALITY CONTROL TESTING INCLUDES

Sterility
TCID50
Protein Concentration
Virus Particle Count

SHIPPING AND STORAGE:

This product is shipped frozen on dry ice. Store at -70°C upon receipt. Avoid multiple freeze-thaw cycles as product degradation may result.

RECOMMENDATIONS:

Before use, rapidly thaw frozen vial in a water bath set at 37°C and then store on ice. Use pre-cooled medium/buffer for virus dilution and store on ice before inoculating into cell culture. For future use, aliquot into small amounts and freeze rapidly in a dry ice/alcohol bath and store at -70°C. Do NOT store virus stock at 2–8°C.

SAFE HANDLING RECOMMENDATIONS:

This preparation of RSV is a BIOHAZARDOUS material containing ACTIVE VIRUS and should be handled in accordance with biosafety guidelines defined in the BMBL, NIH-CDC HHS Publication No. (CDC) 21-1112.

DOCUMENTATION

Certificate of Analysis

Safety Data Sheet

300-10-247-000

REFERENCE ARTICLES

Khan, A., Ng, S., Vandeputte, O., Aljanahi, A., Deyati, A., Cassart, J., Charlebois, R., and Taliaferro, L. (2017). A Multicenter Study To Evaluate the Performance of High-Throughput Sequencing for Virus Detection. mSphere 2, e00307-17. https://doi.org/10.1128/msphere.00307-17

Flynn, J., Durr, E., Swoyer, R., Cejas, P., Horton, M., Galli, J., Cosmi, S., Espeseth, A., Bett, A., and Zhang, L. (2016). Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein. PLOS ONE 11, e0164789. https://doi.org/10.1371/journal.pone.0164789

Saravia, J., You, D., Shrestha, B., Jaligama, S., Siefker, D., Lee, G., Harding, J., Jones, T., Rovnaghi, C., and Bagga, B. et al. (2015). Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33. PLOS Pathogens 11, e1005217. https://doi.org/10.1371/journal.ppat.1005217

You, D., Siefker, D., Shrestha, B., Saravia, J., and Cormier, S. (2015). Building a better neonatal mouse model to understand infant respiratory syncytial virus disease. Respiratory Research 16:91. https://doi.org/10.1186/s12931-015-0244-0

Cormier, S., Shrestha, B., Saravia, J., Lee, G., Shen, L., DeVincenzo, J., Kim, Y., and You, D. (2014). Limited Type I Interferons and Plasmacytoid Dendritic Cells during Neonatal Respiratory Syncytial Virus Infection Permit Immunopathogenesis upon Reinfection. Journal Of Virology 88, 9350-9360. https://doi.org/10.1128/jvi.00818-14

Huang, H., Saravia, J., You, D., Shaw, A., and Cormier, S. (2014). Impaired gamma delta T cell-derived IL-17A and inflammasome activation during early respiratory syncytial virus infection in infants. Immunology And Cell Biology 93, 126-135. https://doi.org/10.1038/icb.2014.79

CATALOG #

PRODUCT NAME

SIZE

PRICE

PRODUCTS